phenylalanine has been researched along with pomalidomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P | 1 |
| Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M | 1 |
2 trial(s) available for phenylalanine and pomalidomide
| Article | Year |
|---|---|
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2020 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide | 2022 |